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Angiotensin type 2 receptor is expressed in the adult rat kidney of the AT1R in the kidney have been clarified, but the
and promotes cellular proliferation and apoptosis. presence and function of the AT2R in the adult rat kid-
Background. Angiotensin II (Ang II) is associated with cell ney remain controversial. The AT2R is a seven-trans-proliferation and apoptosis. The role of the angiotensin type 2
membrane domain receptor, and the cDNA for this re-receptor (AT2R) in these processes remains controversial. Con-
ventional radioligand binding of 125I-Sar1, Ile8 Ang II in adult ceptor has been cloned [1, 2]. It was shown that the AT2R
kidney has failed to demonstrate the binding for the AT2R. was mainly expressed in fetal tissues [3] and neonatal
Methods. The presence of the AT2R was explored in adult rat kidneys [4, 5], which implies that the AT2R might havekidney by in vitro and in vivo autoradiography using the selective
a role during kidney organogenesis. Expression of theAT2R radioligand 125I-CGP 42112B. The roles of the angiotensin
type 1 receptor (AT1R) and the AT2R in mediating cellular pro- AT2R in the kidney decreases after birth [3, 4] and only
liferation and apoptosis were assessed using selective AT1R or very low expression of the AT2R in adult rat kidney has
AT2R antagonists in Ang II-infused Sprague-Dawley (SD) rats. been demonstrated by immunohistochemical stainingResults. 125I-CGP 42112B binding was demonstrated by in vitro
techniques [5, 6]. The expression of the AT2R has alsoand in vivo autoradiography techniques in the glomeruli and
proximal tubules of SD rats. This binding could be displaced been shown in adult monkey [7] and in adult human
by Ang II and the AT2R antagonist PD123319 but not by the kidney [8]. However, conventional radioligand binding
AT1R antagonist valsartan. Subcutaneous infusion of Ang II studies using 125I-Sar1, Ile8 angiotensin II (Ang II) havefor 14 days in eight-week-old SD rats induced proliferation
failed to demonstrate binding for the AT2R in the adultof proximal tubular epithelial cells, as assessed by a twofold
increase in proliferating cell nuclear antigen (PCNA)-positive rat kidney [7, 9, 10].
cells and apoptosis, as assessed by a threefold increase in termi- It has been suggested that the balance between cell
nal dUTP nick end labeling (TUNEL)-positive cells. The ad- proliferation and apoptosis plays an important role inministration of the AT2R antagonist PD123319 or the AT1R
the pathophysiology of various renal diseases [11–13].antagonist valsartan was associated with attenuation of the
increases in both PCNA- and TUNEL-positive cells following Ang II has been clearly demonstrated to induce both
Ang II infusion. Ang II infusion was associated with increased cellular proliferation [14, 15] and apoptosis [16, 17]. It
osteopontin gene and protein expression, which could be re- has been postulated that the AT1R and AT2R haveduced by treatment with either valsartan or PD123319.
opposing actions on proliferation and apoptosis, al-Conclusion. These findings indicate that there is significant
expression of the AT2R in the adult kidney, and that the AT2R though this issue remains controversial [18–20]. The pro-
has a role in mediating Ang II-induced proliferation and apo- liferative properties of Ang II are considered to be asso-
ptosis in proximal tubular epithelial cells and expression of ciated with the AT1R, whereas the AT2R is viewed toosteopontin.
promote apoptosis [18, 19, 21]. However, other studies
have suggested an association of the AT1R with apopto-
sis [22] and the AT2R with proliferation [20]. A furtherAt least two angiotensin receptor subtypes have been
role of AT2R in the kidney has been recently suggestedidentified and classified: the angiotensin type 1 receptor
by a study in which Ang II-stimulated expression of the(AT1R) and the type 2 receptor (AT2R). The functions
chemokine RANTES, which promotes glomerular influx
of monocytes, is mediated by the AT2R rather thanKey words: angiotensin II, receptor subtypes, autoradiography,
CGP42112B peptide ligand, osteopontin expression. the AT1R [23]. It has been shown that osteopontin, an
extracellular matrix protein that is associated with tubu-Received for publication February 15, 2000
lar injury, is stimulated by Ang II [22]. Whether theand in revised form June 20, 2000
Accepted for publication June 22, 2000 effect of Ang II on osteopontin expression is mediated
by the AT1R or the AT2R remains unknown.Ó 2000 by the International Society of Nephrology
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The aims of the present study were, first, to explore formed using in vitro binding techniques as previ-
ously described [27]. First, maximum specific binding ofthe localization of AT2R in the adult rat kidney by using
in vitro and in vivo autoradiography with a selective 125I-CGP42112B in the adult kidney was explored by
increasing the concentration of this radioligand from 3.8AT2R ligand, CGP42112B [24], which has been used to
demonstrate the presence of AT2R in rat brain [25], and to 45 pmol/L in the absence (total binding) or the pres-
ence (nonspecific binding) of 1025 mol/L nonradioactivesecond, to study the roles of the AT1R and AT2R on
cell proliferation, apoptosis, and osteopontin expression CGP42112B. Based on these pilot studies, 125I-CGP42112B
was used in subsequent experiments at a concentrationin response to chronic Ang II infusion.
that achieved .90% maximum specific binding, 15 pmol/L.
To calculate the dissociation constant, 125I-CGP42112B
METHODS
binding was performed in the presence of increasing
Adult male Sprague-Dawley (SD) rats (Biological Re- concentrations of nonradioactive CGP42112B. The sec-
search Laboratory, Austin and Repatriation Medical tions were preincubated for 15 minutes in 10 mmol/L
Center, Heidelberg, Australia) at the age of 8 (N 5 49) sodium phosphate buffer (pH 7.4) followed by an hour
and 24 weeks (N 5 15) were used in this study. The of incubation in a fresh volume of the same buffer con-
protocols for animal experimentation and the handling taining 125I-CGP42112B, 0.1% bovine serum albumin
of animals are in accordance with the principles set out (BSA), and 0.3 mmol/L bacitracin. After incubation, the
by the National Health and Medical Research Council sections were washed four times for one minute each in
and the Animal Welfare Committee of the Austin and ice-cold buffer and air dried at room temperature.
Repatriation Medical Center. Second, to assess the specificity of 125I-CGP42112B
binding, studies of 125I-CGP42112B in the kidney sections
Protocol 1
were performed in the presence of 1025 mol/L of Ang II
Preparation of 125I-CGP42112B. The AT2R peptide li- (Auspep, Parkville, Victoria, Australia), the AT1R an-
gand CGP42112B (a generous gift from Dr. Marc de tagonist valsartan (Novartis Pharma AG), or the AT2R
Gasparo, Novartis Pharma AG, Basel, Switzerland) was antagonist PD123319 (Parke-Davis, Ann Arbor, MI,
iodinated using the chloramine-T method [26] with some USA) in the incubation buffer.
minor modifications. In brief, CGP42112B was combined Third, to determine whether the 125I-CGP42112B bind-
at approximately 10 times molar excess with 125I (ICN ing sites are G-protein–coupled receptors, the nonhy-
Pharmaceutical, Irvine, CA, USA) and 6.2 mg in 10 mL of drolysable GTP analogue guanosine 59-0-(3-thiotriphos-
0.2 mol/L phosphate buffer (pH 7.2) containing 0.005 mol/L phate) (GTP-g-S; Boehringer Mannheim, Mannheim,
Na2 ethylenediaminetetraacetic acid (EDTA). Sodium Germany) was added to the binding buffer at a concen-
azide (0.1%) was added to 1 mCi in 10 mL of the iodine tration of 1.25 mmol/L [28].
solution. The reaction was commenced with addition of All slides, including a set of radioactive standards, were
50 mL of chloramine-T and 0.5 mg/mL of iodination buffer exposed to Kodak BioMax x-ray film at room tempera-
and mixed continually on a custom-made micromixer for ture for five days [9]. Following exposure, the films were
60 seconds. The reaction was terminated with the addition processed, and the optical densities were quantitated
of 50 mL of sodium metabisulfite 0.5 mg/mL in iodination using a microcomputer imaging device (MCID Imaging
buffer. The products were then loaded directly onto system; St. Catherines, Ontario, Canada) connected to an
a mBondapak C18 3.9 3 300 mm high-performance IBM AT computer [9].
liquid chromatography column (waters) and eluted with In vivo CGP42112B binding and autoradiography. In
24% acetonitrile in triethylamine phosphate (TEAP) vivo 125I-CGP42112B binding studies were performed us-
buffer (pH 3.0) at 1 mL/min. The 125I-monoiodinated ing in vivo localization techniques as previously de-
CGP42112B was separated from free 125I and nonlabeled scribed [28]. In brief, 8- (N 5 10) and 24-week-old (N 5
peptide by this method, the specific activity for 125I-mono- 10) SD rats were anesthetized by an intraperitoneal in-
iodinated CGP42112B being 2175 Ci/mmol (1602 mCi/mg). jection of pentobarbital sodium (60 mg/kg). A midline
In vitro CGP42112B binding and autoradiography. The incision into the abdomen was made, and the right kidney
kidneys of SD rats at the age of 8 (N 5 5) and 24 weeks was ligated and removed. The abdominal aorta was can-
(N 5 5) were harvested after the animals were anesthe- nulated with a 20-gauge needle. Following injection of
tized with intravenous injection of pentobarbitone so- 1 mL of phosphate-buffered saline (PBS) alone or PBS
dium (60 mg/kg). The kidneys were removed, bisected, containing 1025 mol/L of Ang II, valsartan, PD123319,
and snap frozen in liquid nitrogen-cooled isopentane and or nonradioactive CGP42112B (N 5 4/per group), ap-
stored at 2208C. Embryonic tissue (E15, N 5 3) was proximately 6 pmol of 125I-CGP42112B in 1 mL of 0.1
used as a positive control. Twenty micron sections were mol/L PBS (pH 7.4) was infused and circulated for 15
cut on a cryostat at 2208C for in vitro binding studies. minutes. Perfusion with PBS was performed for one
minute at 130 mm Hg and then followed by 10% neutral-Autoradiographic localization of the AT2R was per-
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Fig. 1. Representative macroscopic autoradiographs of in vitro total binding for 125I-CGP42112B in rat embryo (A, total binding; D, nonspecific
binding) and the kidney sections from rats at the age of 8 (B, total binding; E, nonspecific binding) and 24 weeks (C, total binding; F, nonspecific
binding). Reproduction of this figure in color was sponsored by Novartis Pharmaceuticals.
buffered formalin for one minute. The kidney was then ously implanted in the midscapular region. The mini-
pump contained either vehicle (control, N 5 7), humanremoved and bisected. Half of the kidney was snap fro-
zen, and 20 micron sections were cut and exposed to x-ray Ang II at a low dose of 12 ng/min (low-dose Ang II,
N 5 6), or Ang II at a high dose of 58 ng/min. Ratsfilm. The other half of the kidney was fixed in 10%
formalin and embedded in paraffin. Four micron sections infused with high-dose Ang II were randomly allocated
to Ang II infusion alone (high-dose Ang II, N 5 7) orwere cut and then dipped in photographic emulsion (Il-
ford K5; Mt. Waverley, Victoria, Australia) and stored treatment with either valsartan (30 mg/kg/day by gavage,
Ang II 1 valsartan, N 5 7) or PD123319 (830 ng/minin the dark for two weeks. Slides were developed in
phenisol developer (Ilford K5; Mt. Waverley) and fixed via an intraperitoneally implanted Alzet minipump,
Ang II 1 PD123319, N 5 7).and stained with hematoxylin-eosin for subsequent light
microscopy. Systolic blood pressure (SBP) was measured by indirect
tail-cuff plethysmography in prewarmed conscious animalsFor identification of 125I-CGP42112B binding in the
proximal tubules, the kidney sections of the rats used in as previously described [29]. Before the animals were sac-
rificed, glomerular filtration rate (GFR) was measured byin vivo study were stained with a lectin (from Phaseolus
Vulgaris PHA-E; Sigma Chemical Co., St. Louis, MO, using the 99mTc-DTPA method as previously described [30].
The animals were sacrificed after two weeks of treat-USA) at a concentration of 1 mg/mL for one hour at
room temperature [28]. Photographic emulsion was ap- ment by intravenous injection of pentobarbitone sodium
at a dose of 60 mg/kg body weight (Boehringer Ingelheim,plied, and the sections were stored in the dark for two
weeks. The slides were developed in phenisol developer Artarmon, NSW, Australia). The left kidney was re-
moved and weighed and then fixed in 10% formalin andand counterstained with hematoxylin.
processed to paraffin. Four micron sections were cut and
Protocol 2 used for histologic assessment, immunohistochemistry,
and in situ hybridization. To assess apoptosis morpholog-Eight-week-old male SD rats (N 5 34) were anesthe-
tized with enflurane (Ethrane; Abbott Australasia, Kur- ically, the right kidney was prepared for electron micros-
copy [31]. In brief, the right kidney was perfused in vivonal, NSW, Australia). An osmotic minipump (Model 2002;
Alzet Corp., Palo Alto, CA, USA) filled with vehicle at the rat’s SBP via an intra-aortic cannula with saline,
followed by 2.5% glutaraldehyde. One mm3 cube was(0.15 mol/L NaCl, 1 mmol/L acetic acid) was subcutane-
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gen, Denmark). Biotinylated multilink swine anti-goat,
mouse, rabbit immunoglobulin (Dako A/S) was used as
a second antibody, followed by horseradish peroxidase
(HRP)-conjugated streptavidin. Peroxidase activity was
identified by reaction with 3,39-diaminobenzidine tetra-
hydrochloride (DAB; Sigma Chemical Co.) substrate.
For identification of proliferation (PCNA) and apo-
ptosis (TUNEL) within the same section, a dual-colored
immunohistochemical procedure was performed using a
modified method described previously by Lan et al [33].
The sections were first stained with TUNEL and then
incubated in 10 mmol/L sodium citrate buffer (pH 6.0)
in a microwave oven at low power for 10 minutes [33].
The sections were treated with the endogenous alkaline
phosphatase inhibitor levamisole to inhibit endogenous
an antibody to PCNA and alkaline phosphate (AP)-conju-
gated streptavidin was applied. Detection was accom-
plished by using the Dako BCIP/NBT substrate system.
Using this method, TUNEL-positive nuclei were stained
brown, and PCNA-positive nuclei were stained dark blue.
Histomorphometry
Renal tubular damage was assessed in kidney sections
stained with hematoxylin-eosin under a light microscope
in a masked fashion (3400) using an Imaging Analysis
System (AIS; Imaging Research, St. Catherines, Ontario,
Canada) associated with a video camera and computer.
Twenty fields of the tubulointerstitial area were scanned,
and dilated tubulointerstitial areas were measured as a
percentage of the total field. The number of cells posi-
Fig. 2. Total binding (d) and nonspecific binding (s) for 125I-CGP421- tively stained with PCNA or TUNEL was counted manu-
12B (A) and percentage of specific/total binding (B) in the adult kidney
ally in the renal cortical areas and expressed as the PCNA-at increasing concentrations of the radioligand.
or TUNEL-positive cell number per field (3400).
Osteopontin mRNA and protein expression
cut from deep areas of the renal cortex and fixed in 2.5%
Osteopontin mRNA expression was determined by
glutaraldehyde for 12 hours before washing in 0.1 mol/L
in situ hybridization as described previously [22, 34].phosphate buffer for 72 hours. Sections were processed
Osteopontin mRNA probes were generated from the ratby standard procedures [31]. Fifty nanometer sections
smooth muscle osteopontin cDNA (a generous gift fromwere cut and viewed under a JEOL 1200EX transmission
Dr. Richard Johnson, formerly of the Department ofelectron microscope for assessment of apoptosis.
Nephrology, University of Washington, Seattle, WA,
USA, and currently Chief, Renal Section, Baylor CollegeTerminal dUTP nick end labeling
of Medicine, Houston, TX, USA) [35]. After in situ hy-Apoptotic cells were identified by in situ labeling of
bridization, kidney sections were exposed to x-ray film,fragmented DNA using terminal transferase (TdT)-medi-
and the densities of kidney sections on x-ray film wereated deoxy-uridine-59-triphospate (dUTP) nick end label-
quantitated with the MCID system as previously de-ing (TUNEL), which were then detected using immuno-
scribed [36]. The slides were then dipped in photographichistochemical techniques [32].
emulsion and prepared for observation under a micro-
Immunohistochemistry scope. Osteopontin protein expression was assessed by
immunohistochemistry with a murine monoclonal anti-For assessment of cell proliferation, kidney sections
body to osteopontin (also a generous gift from Dr. John-were labeled with a monoclonal antibody to proliferating
cell nuclear antigen (PCNA, PC-10; Dako A/S, Copenha- son) as previously described [22].
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Fig. 3. Representative macroscopic autoradiographs of in vitro 125I-CGP42112B binding. Sections were incubated with 125I-CGP42112B (15 pmol/L)
alone (A) or in the presence of 1025 mol/L of Ang II (B), valsartan (C ), PD123319 (D), nonradioactive CGP42112B (E ), and GTP-g-S (F ).
whereas AT2R binding was determined by assessing the
125I-Sar1, Ile8 Ang II binding in the presence of the AT1R
antagonist losartan (1025 mol/L). Nonspecific binding
was determined in parallel incubations in the presence
of both 1025 mol/L PD123319 and 1025mol/L losartan.
Slides were exposed to x-ray film, and binding density
was quantitated using the MCID system. Autoradiogra-
phy using 125I-Sar1, Ile8 Ang II failed to demonstrate renal
expression of the AT2R; therefore, autoradiography with
125I-CGP42112B was performed to assess AT2R binding.
Statistical analysis
Fig. 4. Data of in vitro binding densities for 125I-CGP42112B in the Data are shown as mean 6 SEM and were analyzed
kidney cortex area were assessed using MCID system. *P , 0.01 vs. by the program Statview SE (Brainpower, Calabasas, CA,total binding.
USA) on a Macintosh G3 Computer (Cupertino, CA,
USA). The dissociation constant (Kd) was calculated us-
Assessment of blockade of the AT1R and ing the software MacLigand [37]. Comparisons of group
AT2R binding means were performed by Fisher’s least significant differ-
ence method. A P value of less than 0.05 was viewed asTo confirm blockade of the AT1R with valsartan and
statistically significant.the AT2R with PD123319, binding densities for the AT1R
and AT2R were determined in kidneys from rats admin-
istrated with high-dose Ang II alone or high-dose Ang II RESULTS
with either valsartan or PD123319. Ang II receptor binding
Protocol 1density was assessed using an analogue of Ang II, 125I-Sar1,
In vitro autoradiography. 125I-CGP42112B binding wasIle8 Ang II [27]. Specific AT1R binding was determined
detected in the rat embryonic tissue and in kidney sectionsby assessment of 125I-Sar1, Ile8 Ang II binding in the pres-
ence of the AT2R antagonist PD123319 (1025 mol/L), from rats aged 8 and 24 weeks (Fig. 1). In the kidney, the
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Fig. 5. Representative macroscopic autoradiographs of in vivo 125I-CGP42112B binding. 125I-CGP42112B was infused into rat aorta following
injection of PBS (A, total binding) or PBS with 1025 mol/L of Ang II (B), valsartan (C ), PD123319 (D), nonradioactive CGP42112B (E ).
binding for 125I-CGP42112B was detected in the renal detected in the glomeruli, proximal, and distal convoluted
tubules and tubulointerstitium (Fig. 6A). This binding wascortex with maximal binding in the inner cortex. The
binding density for 125I-CGP42112B increased with in- not detected in the kidney sections from rats preinjected
with Ang II, PD123319, or nonradiolabeled CGP42112B.creasing concentrations of the radioligand (Fig. 2A).
Ninety percent of specific binding was achieved at the Tissue sections from kidneys preinjected with ligand then
sequentially stained with lectin for identification of proxi-concentration of 15 pmol/L (Fig. 2B).
The binding for 125I-CGP42112B was reduced to levels mal tubules and dipped in photographic emulsion revealed
colocalization of the binding sites for 125I-CGP42112Bequivalent to nonspecific binding in the presence of Ang
II or PD123319, but not in the presence of valsartan and lectin staining, consistent with a proximal tubular site
for 125I-CGP42112B binding (Fig. 6C).(Figs. 3 and 4). 125I-CGP42112B binding in the kidney
was completely abolished in the presence of GTP-g-S
Protocol 2(Figs. 3 and 4). When compared with the binding of
125I-CGP42112B in embryonic tissue (164 6 5 dpm/mm2), Systolic blood pressure, body weight, and kidney weight.
Data for SBP, body weight, and kidney weight are shown125I-CGP42112B binding density was much lower in the
kidneys of 8- (18.2 6 0.4 dpm/mm2) and 24-week-old in Table 1. Ang II infusion resulted in a dose-dependent
rise in blood pressure. The increase in SBP induced by(17.6 6 0.5 dpm/mm2) rats (P , 0.05, respectively). Dis-
sociation constants for125I-CGP42112B binding in the the high-dose Ang II infusion was attenuated by coadmin-
istration of valsartan but not of PD123319. Rats infusedembryo tissue (Kd 3.09 nmol/L) and in the kidneys at 8
(4.47 nmol/L) and 24 weeks (4.30 nmol/L) were all in with Ang II at a high dose or combined with PD123319
gained less weight compared with other groups. Rats inthe same nanomolar range.
In vivo autoradiography. In vivo autoradiography re- these two groups had lower kidney weights than control
rats; however, kidney-to-body weight ratios were highervealed that 125I-CGP42112B binding was localized to the
renal cortex, which was consistent with in vitro autoradi- because of reduced body weight as compared with other
groups.ography (Fig. 5A). 125I-CGP42112B binding was reduced
in the context of concomitant administration of nonradio- Glomerular filtration rate. Angiotensin II infusion at
high dose was associated with reduced GFR when com-active CGP42112B (Fig. 5E). As observed in the in vitro
studies, 125I-CGP42112B binding was reduced in the kid- pared with that detected in control rats (Table 2). This
was not observed in the low-dose Ang II groups. Admin-ney sections from rats preinjected with Ang II (Fig. 5B)
or PD123319 (Fig. 5D), but not reduced in kidney sec- istration of either valsartan or PD123319 was not associ-
ated with changes in GFR. The changes in GFR weretions from rats preinjected with valsartan (Fig. 5C).
By emulsion autoradiography, the binding sites were consistent among rat groups whether filtration rate was
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Fig. 6. Slides coated with photographic emul-
sion showing localization of 125I-CGP 42112B
in vivo binding sites. 125I-CGP42112B was in-
fused into rat aorta following injection of PBS
(A, total binding) or PBS with 1025 mol/L
of nonradioactive CGP42112B (B, nonspecific
binding). Silver grains (black dots) overlying
cells in glomeruli and proximal convoluted
tubules represent 125I-CGP 42112B binding
sites (A and C ). The slide (C) shows double
labeling of photographic emulsion (black dots,
total binding) with lectin stain (brown) in the
kidney section from a rat injected with radio-
ligand. Sections are stained with hematoxylin-
eosin (A and B) or hematoxylin with absence
of eosin (C). Original magnification 3400. Re-
production of this figure in color was spon-
sored by Novartis Pharmaceuticals.
assessed as absolute GFR per minute or as GFR cor- proximal tubular cells were shown to be vacuolated and
atrophic and had condensed chromatin (data not shown).rected for kidney weight (Table 2).
Histologic changes. Angiotensin II infused kidneys were The administration of either valsartan or PD123319 was
associated with reduced tubular injury, as assessed byassociated with proximal tubular cell injury in a dose-
dependent manner. Histologic changes included tubular attenuation of increased tubulointerstitial space (Table 1).
PCNA and TUNEL. Angiotensin II infusion resulteddilation and atrophy and increased tubulointerstitial space
(Table 1). At the electron microscopic level, the injured in an increase in PCNA-positive cells in proximal tubules.
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Table 1. Data for systolic blood pressure, body weight and kidney weight in protocol 2
Kidney/bodyBody weight g
SBP Kidney weight ratio Tubulointerstitial
Group N mm Hg week 0 week 2 weight g g/g3100 space %
Control 7 12462 26566 33666 1.2560.03 3.7760.07 5.860.4
Low-dose Ang II 6 15866ab 25665 343614b 1.2760.03b 3.7360.15b 10.161.0a
High-dose Ang II 7 19965a 26265 27069a 1.1460.03a 4.3060.14a 13.261.2a
Ang II1valsartan 7 12963b 25668 31968b 1.3060.06b 4.0560.12 6.061.4b
Ang II1PD123319 7 20762a 26965 25968a 1.1160.06a 4.3060.12a 8.560.8b
a P , 0.01 vs. control
b P , 0.01 vs. high-dose Ang II
Table 2. Glomerular filtration rate (GFR) in protocol 2 both mRNA and protein expression of osteopontin after
Ang II infusion was reduced by treatment with eitherGFR
GFR mL/min/ valsartan or PD123319.
Group N mL/min 100 g kidney
Control 7 3.0760.14 2.4160.07 Assessment of AT1R and AT2R binding
Low-dose Ang II 6 3.1960.13b 2.5360.14b
Total Ang II binding as assessed by autoradiographyHigh-dose Ang II 6 1.9560.21a 1.9060.11a
Ang II 1 valsartan 3 2.2660.07a 1.8760.11a with 125I-Sar1, Ile8 Ang II was down-regulated following
Ang II 1 PD123319 3 2.0360.25a 1.7960.21a Ang II infusion (Fig. 13A). Concomitant treatment with
a P , 0.01 vs. control valsartan, but not PD123319, further reduced Ang II
b P , 0.01 vs. high-dose Ang II
binding density. Ligand binding densities for the AT1R
subtype were also down-regulated in Ang II-infused rats,
and was further reduced by coadministration of valsartan
This was also dose dependent (Figs. 7 and 8). Treatment but not of PD123319 (Fig. 13A). Binding to the AT2R
with either valsartan or PD123319 was associated with was not detected by autoradiography with 125I-Sar1, Ile8
reduced PCNA-positive cells when compared with rats Ang II. However, using the radioligand 125I-CGP42112B,
with high-dose Ang II infusion without treatment. In binding to the AT2R following Ang II was similar to that
fact, valsartan treatment was associated with a reduction detected in control rats. The binding density of AT2R
in PCNA-positive cells in renal tubules to a level similar was reduced in kidneys from rats treated with PD123319,
to that seen in the kidneys from control rats. The number but was not reduced in rats treated with valsartan.
of PCNA-positive cells in PD123319-treated rats was still
higher than seen in control or valsartan-treated animals.
DISCUSSIONTerminal dUTP nick end labeling-positive cells were
The status of renal AT2R in the adult rat kidney hasincreased in kidney sections from rats with Ang II infu-
been an area of controversy. Initial studies suggestedsion, both at the low and high doses, when compared
that there was no gene expression for the AT2R in adultwith control animals (Fig. 8). Treatment with either val-
kidney [7]. However, using immunohistochemical tech-sartan or PD123319 reduced TUNEL-positive cell num-
niques, it was shown that AT2R protein was present,bers to a level similar to that observed in control kidney.
albeit at low levels, in glomeruli and tubules in rat kidneyUsing double labeling, both PCNA- and TUNEL-posi-
[5, 6]. Recently, using microdissection and reverse tran-tive cells were found in damaged renal tubules, with some
scription-polymerase chain reaction (RT-PCR) method-cells positively stained for both PCNA and TUNEL in
ology, AT2R mRNA has been reported to have a wide-the high-dose Ang II infused rat (Fig. 9).
spread distribution within the rat kidney [38]. In the
Gene and protein expression of osteopontin current study, we have not only demonstrated the pres-
ence and binding characteristics of the AT2R in the adultIn control rats, osteopontin mRNA expression was ob-
rat kidney, but have also assessed its role in mediationserved in the medulla with very little expression in the
of Ang II-induced cellular proliferation, apoptosis, andcortex. Following Ang II infusion, osteopontin mRNA
osteopontin expression.was also expressed in the renal cortex, particularly in
In the present study, the AT2R was demonstrateddamaged tubulointerstitial areas, as well as in the Bow-
in adult rat kidney using the selective AT2R ligandman’s capsule (Figs. 10–12). Osteopontin expression, as
CGP42112B. Compared with rat embryonic tissue, whichassessed by immunohistochemical staining, was consis-
had high expression of the AT2R [3], CGP42112B bind-tent with the expression of osteopontin mRNA. Increased
ing in adult rat kidney was much reduced. However,osteopontin protein expression after Ang II infusion was
observed in proximal tubules (Fig. 12). The elevation of the binding characteristics for such as the dissociation
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Fig. 7. PCNA- and TUNEL-positive cells in proximal tubules were identified as brown in nuclei. Sections showed PCNA-positive cells in control
(A) and high-dose Ang II (C ), Ang II 1 valsartan (E ) or Ang II 1 PD123310 (G ), and TUNEL-positive cells in control (B), high-dose Ang II
(D), Ang II 1 valsartan (F ) or Ang II 1 PD123319 (H). Sections were counterstained with hematoxylin. Original magnification 3400.
Cao et al: Renal angiotensin type 2 receptor2446
AT1R and AT2R mediate Ang II-induced collagen syn-
thesis [42] and increase in nuclear calcium [43]. Further-
more, it has been shown that Ang II-stimulated prolifera-
tion in cultured mouse spleen lymphocytes is mediated
by both AT1R and AT2R [15]. Recently, our group re-
ported that the proliferative and trophic effects of Ang II
on the mesenteric arterial tree were reduced by either
valsartan or PD123319, suggesting that both AT1R and
AT2R may be involved in these processes [44].
Angiotensin II was also shown, in a dose-dependent
manner, to induce apoptosis in renal tubular cells. This
was demonstrated by the immunohistochemical TUNEL
Fig. 8. PCNA- (h) and TUNEL- (j) positive cell numbers in the technique and was confirmed by electron microscopy.proximal tubules following Ang II infusion, and treatment with valsartan
Both the AT1R and the AT2R antagonists attenuatedor PD123319. *P , 0.01 vs. control; †P , 0.01 vs. high-dose Ang II;
#P , 0.05 vs. Ang II 1 valsartan. this effect of Ang II on apoptosis. A number of studies
have suggested that the AT2R rather than the AT1R
promote apoptosis [18, 21, 45]. However, a recent study
constants were similar for both groups to those pre- has suggested that the AT1Rs promote apoptosis in cul-
viously reported for the AT2R [39]. The findings from tured adult ventricular myocytes [46]. These inconsisten-
in vitro and in vivo autoradiographic studies were similar cies between studies may be due to the presence and
and revealed that CGP42112B binding was displaced by relative distribution of angiotensin receptor subtypes in
Ang II and the selective AT2R antagonist PD123319, the in vitro and the in vivo contexts, or could be related
but not by the AT1R antagonist valsartan. This indicates to organ specificity of these receptors.
that the binding of CGP42112B was specific for the The in vivo blockade of the AT1R and AT2R demon-
AT2R. Emulsion autoradiography localized these bind- strated that both receptors have similar effects on prolif-
ing sites to the glomeruli and proximal tubules. These eration and apoptosis in the Ang II infusion model. These
findings are similar to those reported using immunohisto- findings are consistent with the hypothesis that there
chemical staining with a specific antibody to the AT2 may be “cross-talk” between AT1R and AT2R, which
receptor [5, 6]. Furthermore, the CGP 42112B binding coordinates the biological effects of Ang II. The mecha-
density was diminished in the presence of GTP-g-S, con- nism for “cross-talk” between these receptor subtypes
sistent with the renal AT2R receptor being a G-protein– remains unknown. Based on the present study, it is possi-
coupled receptor [40]. ble that the AT1R and AT2R may have opposite actions
Using in vitro autoradiography, we demonstrated that with regard to blood pressure [47], but similar effects on
Ang II infusion was associated with down-regulation of proliferation [15, 42–44], and apoptosis [18, 21, 46] in
the AT1R, but there was no significant change in the certain experimental contexts.
AT2R. Similar effects of Ang II on AT1R and AT2R Although both AT1R and AT2R antagonists reduced
regulation have been demonstrated using immunohisto- PCNA staining, PCNA-positive cell numbers in rats treated
chemistry with specific antibodies to the AT1R and with PD123319 were still higher than those in rats treated
AT2R [6]. Previous autoradiography studies using the with valsartan. This may indicate that the AT1R plays
nonselective Ang II agonist 125I-Sar1, Ile8 Ang II failed a more important role in mediating Ang II-induced pro-
to reveal the presence of an AT2R in the adult rat kidney liferation that the AT2R. However, one must be cautious
[27]. This may be due to the relatively low level of expres- in interpreting the data, since antiproliferative effects of
sion of the AT2R subtype in the adult kidney and autora- the AT2R antagonist were observed in persistent hyper-
diography using 125I-Sar1, Ile8 Ang II not having adequate tension, whereas the effects of the AT1R antagonist oc-
sensitivity to detect this low binding for the AT2R. In curred in the presence of reduced systemic blood pressure.
homogenized tissue, it appears that about 10% of Ang II Following Ang II stimulation, proximal tubular cells
receptors are of the AT2R subtype [41]. A similar por- underwent both proliferation and apoptosis. Using double-
tion of AT2R has been demonstrated in adult human labeling immunohistochemistry, we found both PCNA-
kidney by in situ hybridization [8]. and TUNEL-positive cells in damaged proximal tubules.
In the present study, the Ang II-induced increases in We demonstrated that in some cells there was positive
PCNA-positive cells in the proximal tubules and tubulo- staining for both PCNA and TUNEL after continuous
interstitium occurred in a dose-dependent manner with infusion of Ang II. This provides immunohistochemical
these proliferative effects of Ang II most likely mediated evidence showing that both Ang II-stimulated prolifera-
by both AT1R and AT2R. These results are consistent tion and apoptosis may occur in the same cell. The con-
cept of cells undergoing both proliferation and apoptosiswith previous findings, which have shown that both the
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Fig. 9. Double labeling of TUNEL with PCNA
in the renal tubules after Ang II infusion.
TUNEL positive cells were identified as brown
in nuclei (") and PCNA as dark blue ("");
some cells stained positively for both (*"),
counterstain with eosin. Original magnifica-
tion 31000. Reproduction of this figure in
color was sponsored by Novartis Pharmaceuti-
cals.
Fig. 10. Representative macroscopic autoradiographs of gene expression of osteopontin by in situ hybridization in control (A), high-dose Ang II
(B), Ang II 1 valsartan (C ), and Ang II 1 PD123319 (D). Reproduction of this figure in color was sponsored by Novartis Pharmaceuticals.
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Fig. 11. Slides coated with photographic emulsion showing osteopontin mRNA expression by in situ hybridization in control (A), high-dose Ang
II (C ), Ang II 1 valsartan (E ), and Ang II 1 PD123319 (G ); and immunohistochemical staining of monoclonal antibody to osteopontin in control
(B), high-dose Ang II (D), Ang II 1 valsartan (F ) Ang II 1 PD123319 (G ). Original magnification 3400.
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Fig. 12. Data for gene expression of osteopontin was assessed with
MCID system following Ang II infusion or coadministration of valsartan
or PD123319. *P , 0.01 vs. control; †P , 0.01 vs. high-dose Ang II.
has been reported in a range of pathophysiological situa-
tions, including prolactin-induced involution of the cor-
pus luteum [48], malignancy [49], and vascular injury [50].
Furthermore, the proliferative and apoptotic responses
to injury may share common cell cycle pathways, which
could explain why these processes are often closely linked
in disease states including renal injury [51]. It has been
suggested that this phenomenon occurs as result of ab-
normalities in cell cycle signaling [48] and may reflect a Fig. 13. Binding densities of Ang II (h) and AT1R (j) by autoradiog-
response to tissue injury. In a porcine model of percuta- raphy with 125I-Sar1, Ile8 Ang II (A) and binding density of the AT2R
(h) by autoradiography with 125I-CGP42112B (B). *P , 0.01, vs. control;neous transluminal coronary angioplasty, concomitant
‡P , 0.05 vs. high-dose Ang II.proliferation (PCNA) and apoptosis (TUNEL) were de-
tected in the neointima [50].
The ability of both AT1R and AT2R antagonists to
attenuate renal injury following Ang II infusion suggests the AT2R in influencing cellular proliferation and apo-
that both receptors may mediate tissue injury in this con- ptosis. However, it has been suggested that the AT2R
text, possibly via a common pathway. It has been shown may have other effects. For example, some studies have
that overexpression of osteopontin is associated with shown involvement of the AT2R in sodium retention,
tubulointerstitial injury [22, 52]. Expression of osteopon- pressor sensitivity [54, 55], vasodilation [56], and produc-
tin is also increased by administration of Ang II [22]. In tion of renal nitric oxide [57]. Recent studies have dem-
the present study, these findings have been confirmed onstrated that AT2R knockout mice had increased pres-
with up-regulation of both gene and protein expression sor and antinatriuretic sensitivity in response to Ang II
by Ang II infusion. Intervention with either valsartan or
stimulation when compared with AT2R wild-type mice
PD123319 was associated with a reduction in osteopontin
[58]. The diverse effects of the AT2R must be explored inexpression. This suggests that osteopontin is regulated by
more detail, since there is widespread use of angiotensin-both the AT1R and AT2R. However, osteopontin mRNA
converting enzyme inhibitors and AT1R antagonists asexpression was only reduced by either of AT1R or AT2R
renoprotective drugs, and these different inhibitors of theantagonist to levels that were consistently above those
RAS may have disparate effects on the AT2 receptors.detected in normal kidneys. The effects of dual blockade
of both AT1R and AT2R on osteopontin expression in
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